

# Approved Influenza Vaccines United States, 2008-09 Season

| Vaccine | Trade name      | Manufacturer     | Presentation   | Age group   | Thimerosal Preservative  |
|---------|-----------------|------------------|--|---|--|
| TIV     | <b>Fluzone</b>  | sanofi pasteur   | <ul style="list-style-type: none"> <li>•.25 mL prefilled syringe</li> <li>•0.5 mL prefilled syringe</li> <li>•0.5 mL vial;</li> <li>•5.0 mL multi-dose vial</li> </ul> | <ul style="list-style-type: none"> <li>•6-35 mo</li> <li>•<math>\geq</math> 36 mo</li> <li>•<math>\geq</math> 36 mo</li> <li>•<math>\geq</math> 6 mo</li> </ul> | <ul style="list-style-type: none"> <li>•None</li> <li>•None</li> <li>•None</li> <li>•Yes</li> </ul>                      |
| TIV     | <b>Afluria</b>  | CSL              | <ul style="list-style-type: none"> <li>• 0.5 mL prefilled syringe</li> <li>•5.0 multi-dose vial</li> </ul>   | $\geq$ 18 years   | <ul style="list-style-type: none"> <li>•None</li> <li>•Yes</li> </ul>  |
| TIV     | <b>Fluvirin</b> | Novartis Vaccine | <ul style="list-style-type: none"> <li>•0.5 mL prefilled syringe</li> <li>•5.0 mL multi-dose vial</li> </ul>   | $\geq$ 4 years  | <ul style="list-style-type: none"> <li>•Preservative free (<math>\leq</math>1 mcg mercury/dose)</li> <li>•Yes</li> </ul> |
| TIV     | <b>Fluarix</b>  | GSK              | <ul style="list-style-type: none"> <li>•0.5 mL prefilled syringe</li> </ul>  | $\geq$ 18 years   | <ul style="list-style-type: none"> <li>•Preservative free (<math>\leq</math>1 mcg mercury/dose)</li> </ul>               |
| TIV     | <b>FluLaval</b> | GSK/IDB          | <ul style="list-style-type: none"> <li>•5.0 mL multi-dose vial</li> </ul>  | $\geq$ 18 years   | <ul style="list-style-type: none"> <li>•Yes</li> </ul>   |
| LAIV    | <b>FluMist</b>  | MedImmune        | <ul style="list-style-type: none"> <li>•Single-dose sprayer</li> </ul>   | 2-49 years  | <ul style="list-style-type: none"> <li>•None</li> </ul>  |

# Projected Influenza Vaccine Supply, 2008-09 Season

- Estimated total of ~150 million doses will be available from 6 manufacturers
- Estimated total thimerosal- or preservative-free capacity expected to increase to ~50 million doses

# ACIP: New Influenza Vaccination Recommendations for Children

*All children aged 6 months through 18 years should receive annual influenza vaccination, beginning in 2008 if feasible, but beginning no later than during the 2009-2010 influenza season*

**\*Approved at February 27, 2008 ACIP meeting**



# Recommendation Change for Influenza Vaccination: 2008-09 Season

## **Before 2000:**

Persons aged 65 or older

Persons with chronic medical conditions that make them more likely to have complications of influenza

Pregnant women in the second or third trimester

Contacts (household and out of home caregivers) of the above groups

Healthcare workers

**2000:** Adults 50 and older

**2004:** Children aged 6–23 months

Contacts (household and out of home caregivers) of children aged 0–23 months

Women who will be pregnant during influenza season

**2006:** Children aged 6–59 months

Contacts (household and out of home caregivers) of children aged 0–59 months

**2008:** **All children aged 6 months–18 years**


# Recent Influenza Vaccine Coverage Data, United States

Source: L Williams, NCIRD/ISD/ISSB  
G Euler, NCIRD/ISD/AB



# Percentage of children who received 1 or more doses of influenza vaccine among children 6-23 months of age, IIS Sentinel Site Project, 2004-05 through 2007-08 influenza seasons


## Preliminary Data



\*Note: OR sentinel site expanded from Washington County in 2004-5 through 2006-7 seasons to include Multnomah county in 2007-8 season. Michigan added one county to its sentinel site region in 2007-8 season.

Percentage of children fully vaccinated (i.e., 1 or 2 doses as appropriate) against influenza among children 6-23 months of age, IIS Sentinel Site Project, 2004-05 through 2007-08 influenza seasons


Preliminary Data



\*Note: OR sentinel site expanded from Washington County in 2004-5 through 2006-7 seasons to include Multnomah county in 2007-8 season. Michigan added one county to its sentinel site region in 2007-8 season.

Percentage of children fully vaccinated (i.e., 1 or 2 doses as appropriate) against influenza among children 24-59 months of age, IIS Sentinel Site Project, 2006-07 & 2007-08 influenza seasons


Preliminary Data



\*Note: OR sentinel site expanded from Washington County in 2004-5 through 2006-7 seasons to include Multnomah county in 2007-8 season. Michigan added one county to its sentinel site region in 2007-8 season.



# Self-Reported Influenza Vaccination Coverage Levels Among Selected Priority U.S. Adult Populations, 1989-2007\*, National Health Interview Survey




Source: CDC, NHIS. <http://www.cdc.gov/flu/professionals/vaccination/pdf/vaccinetrend.pdf>

\*Preliminary data from 2006-07 influenza season



**FIGURE. Estimated number of persons reporting vaccination\* for influenza, by month — United States, National Health Interview Survey, 2005–06 and 2006–07 influenza seasons**



MMWR 2007;56:1217

# ACIP Influenza Vaccine Workgroup Activities and Discussion Topics, 2008

- Routine annual vaccination of healthy adults ages 19–49
  - Report requested by Dr. Morse, February 2008 ACIP meeting
    - Workgroup to report to ACIP within 1 year
  - Assess evidence base
  - Evaluate impact of current recommendations on disease among healthy adults
  - Consider potential impact of new recommendation for annual vaccination of all children on disease among healthy adults
  - Consider timeframe

# Critical Factors: Annual Influenza Vaccination Recommendations for Healthy Young Adults

- Vaccine supply
- Vaccine safety
- Vaccine effectiveness
- Disease burden
- Cost-effectiveness
- Feasibility of sustained implementation
- Timeframe

# ACIP Influenza Vaccine Workgroup Activities and Discussion Topics, 2008

- Pandemic and pre-pandemic influenza vaccine issues
  - Provide comment on HHS and other Federal plans
- Monitor trends in antiviral resistance to determine if ACIP recommendations for influenza treatment or prophylaxis need revision
  - Supplement workgroup with clinical experts as needed
- Consider issues related to new influenza vaccine recommendations for children
  - Implementation challenges
  - Measuring impact

# Influenza Vaccine Working Group Members

## Kathy Neuzil, Chair

- **Jan Englund**
- **Patsy Stinchfield**
- Nana Bennett (NAACHO)
- Hank Bernstein (AAP)
- Richard Clover (AAFP)
- Jeff Duchin (NAACHO)
- Stanley Gall (ACOG)
- Elyse Olshen Kharbanda (SAM)
- **Susan Lett** (CSTE)
- Tamara Lewis (AHIP)
- William Schaffner (NFID)
- Rob Schechter (AIM)
- Danuta Skowronski (NACI)
- LJ Tan (AMA)
- Joe Bresee (CDC)
- Carolyn Bridges (CDC)
- Karen Broder (CDC)
- Nancy Cox (CDC)
- Therese Cvetkovich (FDA)
- David Delozier (CDC)
- Scott Epperson (CDC)
- Wayne Hachey (DoD)
- John Iskander (CDC)
- Gina Mootrey (CDC)
- Jeanne Santoli (CDC)
- Ben Schwartz (CDC)
- David Shay (CDC)
- Jean Clare Smith (CDC)
- Ray Strikas (NVPO)
- Rosemary Tiernan (FDA)
- Mary Vernon-Smiley (CDC)
- Greg Wallace (CDC)